An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2008
At a glance
- Drugs Pneumococcal 11-valent vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Jun 2007 Status changed from in progress to completed.
- 23 Oct 2006 New trial record.